Solid Biosciences (NASDAQ:SLDB) Announces Quarterly Earnings Results

Solid Biosciences (NASDAQ:SLDB) announced its earnings results on Wednesday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.05, Zacks reports.

Solid Biosciences Stock Down 5.2%

NASDAQ SLDB opened at $6.18 on Friday. The firm’s fifty day simple moving average is $7.55 and its two-hundred day simple moving average is $7.66. Solid Biosciences has a 12-month low of $3.79 and a 12-month high of $11.45.

Analysts Set New Price Targets

Several research firms have recently commented on SLDB. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, October 15th. UBS Group initiated coverage on Solid Biosciences in a research report on Wednesday, October 14th. They set a “buy” rating and a $20.00 price objective on the stock. Royal Bank Of Canada began coverage on Solid Biosciences in a research note on Wednesday, September 16th. They issued an “outperform” rating and a $18.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Solid Biosciences in a report on Tuesday, October 27th. Finally, Loop Capital set a $25.00 price target on shares of Solid Biosciences in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.00.

Solid Biosciences Company Profile

Solid Biosciences Inc (NASDAQ: SLDB) is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.